Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences has joined the 3D-PREDICT clinical study, by Kiyatec Inc., to validate the company’s test as a patient-specific predictor of response to recommended drug therapies for patients with ovarian cancer.
“We developed our investigational ovarian cancer drug response profile to help optimize therapeutic decision-making over the course of the disease,” Matthew Gevaert, CEO of Kiyatec, said in a statement.
3D-PREDICT is a prospective, open-label, non-interventional study to validate Kiyatec’s ovarian cancer drug response profile, which leverages the company’s ex vivo 3D cell culture technology platform to assess pre-treatment, patient-specific response to a panel of 11 drugs most commonly used to treat patients with newly diagnosed or recurrent ovarian cancer.
Kiyatec uses its ex vivo 3D cell culture technology platforms to accurately model and predict response to approved and investigational cancer drugs targeting a spectrum of solid tumors.
